Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We finally have enough revenue to cover Bunka's salary. LOL
The net loss has dropped by $1.7 million, not bad!
Hill Street Beverages News.
https://www.newsfilecorp.com/release/78807
My other question is Nic's Beverages using full-spectrum CBD oil for the stability test or an isolate.
I don't think that Altria ever gave the technology a fair look. Soon after the research agreement with Altria was announced the CEO that made the deal with Lexaria was let go and I think the new guy slashed the project out-of-hand. That's why there was never any final report made and no contact with Lexaria after the project was supposed to be finished. They dropped the project and just forgot about it.
Hopefully, BAT will completely evaluate our technology and we will then have a good idea of its commercial value.
Bunka doesn't say what kind of container they used or whether they tried various types of containers or not. I'm really interested to hear more details about their stability testing and direct comparisons to other products' stability.
Sickening to see what we're missing out on! Nobody seems to need or want our tech for beverages.
https://investorplace.com/2021/03/drink-up-the-continued-gains-in-aphria-apha-stock/
Rapid Progress in Hypertension Studies by Lexaria
(via TheNewswire)
• Five studies underway to examine DehydraTECHTM CBD for Hypertension
Kelowna, British Columbia - TheNewswire - March 15, 2021- Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CNSX:LXX.CN) (OTC:LXRP) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces extensive progress in five studies focused on the performance of DehydraTECHTM CBD as a treatment for hypertension. Three human clinical trials and two animal research trials are part of the Company’s 2021 applied research and development (R&D) program. The Company has additional studies under design, to be announced when available. Lexaria’s DehydraTECH CBD for hypertension studies are being performed by third-party laboratories to ensure study objectivity.
DehydraTECH CBD For Hypertension.
All five of the planned 2021 hypertension studies are underway:
HYPER-A21-1: Dosing is comple te and sample analysis is underway in this animal study. No observed behavioural tolerability issues were noted during or after dosing. This study is evaluating the rate of absorption and speed with which various new enhanced DehydraTECH experimental formulations – “DehydraTECH 2.0” – deliver CBD to the bloodstream and brain. Enhanced DehydraTECH 2.0 formulations represent next-generation drug delivery enhancements not yet commercially available anywhere in the world. Results should be reported in or around the first half of May.
HYPER-A21-2: Dosing is scheduled to begin next week and is expected to be completed in this animal study by March 30. This study is also evaluating the rate of absorption and speed with which additional enhanced DehydraTECH 2.0 formulations deliver CBD to the bloodstream and brain. Results should be reported in or around the first half of June.
Studies HYPER-A21-1 and HYPER-A21-2 may contribute to superior performance in future generations of commercial products, and also to formulation enhancement in human studies contemplated for late 2021 and 2022. Additional work pursuant to these studies is also expected that will evaluate impacts upon real-time blood pressure in animals at the doses studied.
HYPER-H21-1: Regulatory importation clearance was received for the clinical test articles for this human study which have arrived at the European research site. Following this, recruitment of the 24 volunteers with otherwise untreated pre- or mild-hypertension has begun. Human dosing – using a single 300mg dose of CBD with or without DehydraTECH formulation enhancement - is tentatively expected to be complete by May. A particular DehydraTECH 2.0 formulation will be evaluated in this study. Time series blood pressure and heart rate analyses are the primary objectives of this study. Secondary objectives include speed and rate of absorption of the CBD and its main metabolites (pharmacokinetics or “PK” assessments), as well as evaluation of inflammatory markers associated with cardiovascular disease and gold-standard biomarkers of nitric oxide. This latter measure provides mechanistic insight into the anticipated reduction in blood pressure via vasodilation. Inflammatory marker assessments may also be applicable to Lexaria’s research initiatives in the antiviral therapeutics space whereby effective anti-inflammatory therapies are also useful in treating diseases like COVID-19 or other common pro-inflammatory conditions. Since a large array of data points will be generated and analyzed, final reporting on this study is likely to be reported in early September or thereabouts, though preliminary outcomes may be reported before then.
HYPER-H21-2: Formal hospital and ethics board applications for this upcoming European human clinical study have been approved and test articles are expected to arrive at the research site as early as next week. Following this, recruitment of 16 volunteers will commence soon in this study. A particular DehydraTECH 2.0 formulation will again be utilized in this study. As in HYPER-H21-1, volunteers will be pre- or mildly-hypertensive males and females aged 45-70 years. In this study, however, volunteers will consume three separate doses of 150mg of DehydraTECH CBD or placebo that will be split over a 24-hr period, and be monitored continuously via ambulatory (portable) monitoring technology throughout this time. The primary objectives of this study are blood pressure and heart rate evaluation, while the secondary objectives include central arterial stiffness, physical activity and sleep quality (e.g., total sleep time, total wake time, and sleep efficiency). Once again, a large array of data points will be generated and analyzed and final reporting on this study is likely to be reported in late September or thereabouts, though preliminary outcomes may be reported before then.
HYPER-H21-3: Formal hospital and ethics board approvals for this upcoming European human clinical study have also been received and test articles are also expected to arrive at the research site as early as next week. Following this, 16 volunteers will be recruited once recruitment in studies HYPER-H21-1 and HYPER-H21-2 is complete. In a placebo-controlled and blinded design, a single 300mg dose of a particular DehydraTECH 2.0 CBD formulation will be administered in this “Stress Test” study to examine its effect on acute pulmonary hypertension. Exposure to acute reductions in oxygen tension (i.e., hypoxia) causes rapid hypoxic pulmonary vasoconstriction (HPV) and, as a consequence of this HPV response, pulmonary arterial pressure increases. If this increase in pressure becomes too high, as is the case in many cardiac pathologies, an excess of fluid in the lungs can occur that causes difficulty with breathing. The extent to which CBD may act as a novel treatment for HPV, and potentially as an alternative treatment for pulmonary hypertension, is unknown. Thus, the primary objective of this study is to evaluate the effect of DehydraTECH CBD on pulmonary vascular function in normotensive individuals exposed to hypoxia. The magnitude of HPV, blood pressure, heart rate, blood samples (as per HYPER-H21-1 , see above), and pulmonary gas exchange data will be collected and analyzed. Details will be furnished at a future date on the likely timing of reporting from this study once recruitment has begun.
The five studies in Lexaria’s 2021 DehydraTECH CBD hypertens ion program are expected to generate data required to further support the validity of using DehydraTECH CBD as a potential anti-hypertension treatment across various prospective applications to the US$28 billion annual hypertension drug market. In addition, direct healthcare costs for patients with pulmonary arterial hypertension has been estimated at between US$29,712 and $142,500 per year. Lexaria holds 18 granted patents internationally, including issuances in the European Union and Australia specifically to use DehydraTECH-processed CBD to treat heart disease.
Summary
Lexaria relies on applied R&D programs to generate confirmatory results and data evidencing improved drug delivery characteristics that enable pursuit of commercial opportunities and/or corporate relationships. As such, Lexaria considers advancing these applied R&D studies to be a vital early step toward its goal of establishing commercial relationships with potential industry partners to utilize DehydraTECH within their existing product lines or in the development of new product lines.
All studies referenced within this press release are fully funded from existing Company resources.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
What do you see that you like? The chart looks pretty depressing to me, we seem to be capped by the 50 DMA right now and trapped in an intermediate downtrend.
Thanks, guys.
Do you have the link? I couldn't find anything on SEDAR. Thanks
Don't you have another hair to split somewhere else?
He misled no one. It's just common knowledge that private placements are open to institutions and accredited investors. If you know that and I know that and FK knows that and most experienced investors know that, then how can someone be misled?
Heh did you hear? Bunka is not a scientist.
Wow! Who would have thunk? Both institutions AND qualified investors could have partaken in the private placement, just like every other PP. Wow! Thanks for pointing that out P&P.
Keep up the great tips. I'm learning a lot about the market from you.
Lexaria Bioscience-Chris Bunka
http://www.moneytalkstation.com/lexaria-bioscience-chris-bunka/
Lexaria Enters Investor Relations Agreement
2021-02-16 16:45 ET - News Release
(via TheNewswire)
Kelowna, British Columbia – TheNewswire - February 16, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces its engagement of Accretive Capital LLC, a Delaware limited liability company doing business as Benzinga, to provide investor relations services (“ IR Services ”) to the Company.
The Company has agreed to pay Benzinga US$16,000 for the provision of its IR Services over a one year term. The IR Services shall include the participation of the Company in three Benzinga conferences during the year term, along with marketing the Company on Benzinga’s virual event platform, SmallCap website, in newsletters, social media, video presentation and via editorial coverage.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com .
Lexaria Bioscience (LEXX.NASDAQ) (LEXX.CSE) $11 million financing supports R&D program targeting high blood pressure and SARS-CoV-2 infection
Lexaria Bioscience (LEXX.NASDAQ) (LEXX.CSE) $11 million financing supports R&D program targeting high blood pressure and SARS-CoV-2 infection
Canada NewsWire
VANCOUVER, BC, Feb. 16, 2021
VANCOUVER, BC, Feb. 16, 2021 /CNW/ - Lexaria Bioscience's (NASDAQ: LEXX) (CSE: LEXX) drug delivery technology, DehydraTECHTM improves the "bioavailability" of pharmaceutical ingredients.
"Bioavailabilit y is the rate and extent to which a therapeutically active substance enters systemic circulation and becomes available at the required site of action," states the U.S. National Library of Medicine.
Last month, LEXX raised USD $11 million. On February 1, 2021, LEXX announced an ambitious R&D strategy to advance DehydraTECHTM towards commercial exploitation in two main sectors: high blood pressure and anti-viral drugs.
Intravenous needles are the holy grail of bioavailability - delivering 100% efficiency - which is why hospital patients are typically on an I.V. drip.
Orally ingested drugs "must pass through the intestinal wall and then the portal circulation to the liver," explains Merck Manual, "both are common sites of First-Pass Metabolism".
During The First Pass Effect drugs are metabolized in the liver - resulting in a lower concentration of active drugs in the blood system.
A technology that can reduce The First Pass Effect for many drugs will achieve two significant outcomes: 1. increased medical benefits to patients and 2. higher profits to pharmaceutical companies.
DehydraTECH-CBD For Hypertension
On July 28, 2020 Lexaria received European ethics board approval to conduc t a clinical study using a DehydraTECH™-CBD formulation to assess blood pressure reduction potential in volunteers with pre- or mild-hypertension.
The global CBD market is "expected to reach $23.6 billion in 2025," according to Grandview Research.
"Hypertension [high blood pressure] is a $30 billion a year market," explains Chris Bunka, CEO of Lexaria, "Over 1 billion people around the world suffer from this condition".
Scanning the last 10 years of LEXX Insider Filings – there are no recorded sales of Lexaria shares by Mr. Bunka, but more than 75 incidences of Bunka purchasing shares on the open market, increasing his ownership position to 10% in 2021.
The Study will be a double-blinded, placebo-controlled, cross-over pilot study in which 24 volunteers will be randomized to receive a 300 mg dose of CBD with or without DehydraTECHTM.
In a "double blind study", neither the participants nor the investigators know who is receiving a particular treatment.
Formulations of DehydraTECH-processed CBD will be util ized including recent enhancements intended to further optimize the delivery of CBD in the animal test groups.
Additional planned study work in 2021 will include a second human clinical study in pre-and mildly-hypertensive subjects, pending regulatory clearances.
"Following on our 2018 study, we intend to demonstrate a linear improvement in delivering lower blood pressure," stated Bunka.
"Later in 2021, we hope to start knocking on the doors of pharmaceutical partners who already have hypertension drugs in the market place."
DehydraTECH with Antivirals for COVID-19
On December 1, 2020, Lexaria announced that, in an animal study, DehydraTECHTM "significantly improved delivery in two classes of antiviral therapies under investigation against SARS-CoV-2/COVID-19 and already in use against HIV/AIDS".
Lexaria will be testing four antiviral drugs including remdesivir, a nucleotide reverse transcriptase inhibitor and three additional drugs known to target the main protease associated with SARS-CoV-2 infection.
The first of these studies VIRAL-A20-2, has completed its initial design phase and animal dosing is expected to occur in February/March, 2021 with results in May/June followed by analysis and reporting.
"The data that we generate from this R&D campaign is applied research," Mr. Bunka told Proactive on Feb 1, 2021, "it allows us to enter meaningful discussions with potential commercial partners".
"What we are trying to do is expand the list of drugs that will work with our technology," added Bunka.
Full Disclaimer
View original content:http://www.prnewswire.com/news-releases/lexaria-bioscience-lexxnasdaq-lexxcse-11-million-financing-supports-rd-program-targeting-high-blood-pressure-and-sars-cov-2-infection-3 01228385.html
Because you have to find the cure first and then perhaps we could provide the delivery system for that potential drug.
Donnelly has resigned!
Hill Street Welcomes Raymond Bisaillon to the Board of Directors
Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - Hill Street Beverage Company Inc. (TSXV: BEER) ("Hill Street" or the "Company") is pleased to announce that it has appointed Raymond Bisaillon to the board of directors of the Company.
Jack Fraser, Chairman of the Board stated, "We are very excited to welcome Raymond to the Board of Directors of Hill Street, as his past success & fresh approach to this rapidly expanding sector compliments the talents of the company's already rich assets."
His appointment comes at a time when Hill Street is poised to leverage the recent acquisition of the exclusive rights to Lexaria's ground-breaking DehydraTECHTM patent portfolio on a global basis. Mr. Bisaillon commented that "I am of the strong belief that DehydraTech is the safest, healthiest and most simple method to infuse the numerous attributes of the Cannabis plant into the bloodstream and am thrilled to partner with Hill Street Beverage Company in expediting the commercialization of this valuable patented technology. I am excited to help guide Hill Street Beverage Company through the next phase of its growth to become a unique shareholder friendly, health conscious, profitable Company."
Raymond Bisaillon
Mr. Bisaillon is a calculated, thoughtful, philanthropic entrepreneur and private investor who has had a successful passion for investing since an early age. In his quest to follow in the footsteps of legendary investors, he has taken calculated risks in excellent businesses that possess a unique competitive advantage.
As a proud graduate of Laurentian University, Raymond was fortunate to have been selected to represent the country of Canada as a member of AISEC in Sao Paulo, Rio de Janeiro, Vitoria and Salvador Brazil in 1997. In 1998, he was a Canadian Student Ambassador i n the Sichuan Province of China to encourage International Trade Relations.
Upon graduation in 1999, Raymond worked as a Certified Financial Planner (CFP) and Canadian Investment Manager (CIM) with Industrial Alliance Insurance and then in 2002 as a Senior Financial Advisor with CIBC Imperial Service. In 2012, he launched Bisaillon Asset Management Inc, a full-service Financial Planning Firm in Sudbury ON.
About Hill Street Beverage Company Inc. (TSXV: BEER)
Hill Street Beverage Company is a leading and award-winning company focused on alcohol-free beer, wine, and adult-format beverages. Hill Street's brands include Hill Street Craft Brewed Lager, Vin(Zero) and Vintense wines, and have won numerous medals and accolades around the world. Hill Avenue Cannabis, the Company's wholly-owned subsidiary, will produce and sell cannabis-infused adult beverages and other cannabis products with expected distribution at licensed outlets in 2021. Check out Hill Street's award-winning line-up and order product to be delivered straight to your home at www.hillstreetbeverages.com.
For further information:
Jack Fraser, Chairman of the Board, Hill Street Beverage Company Inc.,
jack@hillstreetbevco.com
Follow Hill Street on Twitter https://twitter.com/hillstreetbevco
and on Facebook http://facebook.com/hillstreetbevco
ORIGINAL: Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies
2021-02-11 07:15 ET - News Release
(via TheNewswire)
- Hypertension program evaluating effectiveness of DehydraTECH-processed CBD now consists of three human clinical studies and two animal studies
Kelowna, British Columbia – TheNewswire - February 11, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces significant progress in its 2021 applied research and development (R&D) program with additional focus on hypertension.
“Over 1.1 billion people suffer from hypertension,” said Chris Bunka, CEO of Lexaria. “Pending successful completion of Lexaria’s study programs, we intend to pursue opportunities for growth through strategic partnerships with leading companies active in the hypertension drug or CBD pharmaceutical marketplaces.”
DehydraTECH-CBD For Hypertension
The overall 2021 Lexaria hypertension program now consists of a total of five studies, three of which were described in the Company’s announcement on February 1, 2021 and updated here (HYPER-A21-1, HYPER-A21-2, and HYPER-H21-1), and two new additions, which are announced now for the first time (HYPER-H21-2 and HYPER-H21-3).
Study design for the Company’s planned animal studies HYPER-A21-1 and HYPER-A21-2 has been completed, and delivery of the formulations to be tested to the third-party laboratories in good condition has been confirmed. Dosing remains on schedule, and is expected to begin in late February or early March.
HYPER-H21-1 as previously announced, and the new additions, HYPER-H21-2 and HYPER-H21-3, are each randomized, double-blinded human clinical studies to take place in Europe. Study design for HYPER-H21-1 is complete and university hospital and ethics board approvals have been received. Subject dosing for HYPER-H21-1 will begin after shipment of the clinical test articles to the clinical site is completed, pending regulatory clearances for importation as previously announced.
HYPER-H21-2 has been added to the Lexaria hypertension program due to the increasing importance that this work could have on Lexaria’s commercial prospects. This study is designed to monitor ambulatory blood pressure during a 24-hour period after subject dosing, with subjects wearing portable devices that will record blood pressure at 30-minute and 60-minute intervals. Volunteers will visit the laboratory three times and receive either a placebo or a 150mg dose of DehydraTECH-CBD, three times daily. The results of this study will contribute to the understanding of the effectiveness of patented DehydraTECH-processed CBD as a potential novel anti-hypertensive agent through the course of a full day of monitoring, which is expected to be complementary to the shorter-term monitoring in HYPER-H21-1. Study design for HYPER-H21-2 is complete and university hospital and ethics board approvals are pending, following which the Company will be able to provide additional details on expected timing of commencement of subject recruitment and dosing.
HYPER-H21-3 is also a double-blinded, placebo controlled, randomized human clinical study that has been added to Lexaria’s hypertension program to complement the data set the Company intends to build. This study is designed to monitor effectiveness of a 300 mg dose of DehydraTECH-CBD relative to placebo on blood pressure in volunteers under conditions of hypoxic pulmonary vasoconstriction. Data from this study may demonstrate utility of DehydraTECH-CBD for blood pressure reduction in circumstances where pulmonary edema/hypertension results as occurs, for instance, when people travel to high altitude regions of the world. Study design for HYPER-H21-3 is complete and university hospital and ethics board applications are under development and should be submitted shortly. Once approvals are received the Company will be able to provide details on timing of executing this study.
The five studies in Lexaria’s 2021 hypertension program are expected to generate data required to further support the validity of using DehydraTECH-processed CBD as a potential hypertension treatment across various applications. Lexaria has received 18 granted patents internationally, including issuances in the European Union and Australia specifically to use DehydraTECH-processed CBD to treat heart disease.
DehydraTECH with Antivirals for COVID-19
As referenced in Lexaria’s announcements on December 22, 2020 and February 1, 2021, VIRAL-C21-3 study is designed to evaluate the relative antiviral activity of certain DehydraTECH formulations in an effort to kill the virus in an established cell culture model of SARS-CoV-2 infected cells. This study protocol design is now complete and commencement of the laboratory work is expected in March, as previously announced.
Lexaria relies on applied R&D programs to generate confirmatory results and data evidencing improved drug delivery characteristics that enable pursuit of commercial opportunities and/or corporate relationships. As such, Lexaria considers these applied R&D studies to be a vital early step in establishing commercial relationships with potential industry partners to utilize DehydraTECH within their existing product lines or in the development of new product lines.
Applied R&D studies often also provide test data that support existing patent applications and, at times, produce data that could support additional new patent applications. (Under Lexaria’s identification protocols, “A21” designates a 2021 animal study, whereas “H21” designates a 2021 human study and “C21” designates a cell culture study.)
All studies referenced within this press release are fully funded from existing Company resources
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com .
Maybe now the new leaders at Hill Street will get their shit together and enter the edibles market, finally!!
Terry Donnelly turfed at Hill Street!
ORIGINAL: Hill Street Appoints Co-Chief Executive Officers
2021-02-09 08:39 ET - News Release
Toronto, Ontario--(Newsfile Corp. - February 9, 2021) - Hill Street Beverage Company Inc. (TSXV: BEER) ("Hill Street" or the "Company") announces that it will be restructuring its senior management team and will be appointing current board members, Lori Senecal and Craig Binkley, as interim co-Chief Executive Officers of the Company. The Company anticipates that Mr. Donnelly, will remain with the Company as a board member until its next AGM.
Jack Fraser, Chairman of the Board stated, "On behalf of Hill Street, I would like to thank Terry for his service to the Company. His expertise and dedication have benefitted the Company in countless ways and we wish him the utmost success in his future endeavours." Adding, that, "We are very excited to welcome Craig and Lori to their expanded roles as Co-CEOs of Hill Street. The extensive knowledge and expertise that Craig and Lori bring at this stage to Hill Street's operating team will help guide the Company into the next exciting phase of its development. Craig and Lori have both have been instrumental over the past years as board members and working directly with the management on strategic projects, and their involvement in the daily management of the organization with help continue to drive our strategic plans. Both Craig and Lori will continue as Interim Co-CEOs of Hill Street until we complete our review for a permanent CEO."
Craig Binkley
Craig Binkley is a successful global business leader and experienced CEO who has built upon his success running global organizations to become a sought-after Advisor and Board Member to clients ranging from Fortune 500 to small business entrepreneurs.
Craig has been on the Board of Hill Street since 2017 and was a member of the team that completed Hill Street's going public transaction in 2018.
Craig brings a wealth of global operating experience in both alcoholic and non-alcoholic beverages, as well as other consumer packaged goods and B2B business categories that are highly relevant for the Hill Street lines of business. He has been actively involved in the global cannabis industry since 2017, focused on helping to accelerate the positive impact of cannabis, hemp and CBD as a thought leader and speaker at global events, as a board member for cannabis-related companies, and by building consumer brands and commercial go-to-market operations across a range of consumer categories within the cannabis sector.
Before entering the professional services arena, Craig was a global leader at The Coca-Cola Company as Worldwide Director of Marketing for Diet Coke & Coca-Cola light, as well as the Minute Maid brand of juices and drinks. He also served as CMO of Coca-Cola Mexico, the second largest Division in the world.
In his professional services work, Craig is currently Managing Partner at Fidelum Partners. Prior to that he was CEO of Northstar - a global, multi-award-winning, market research agency, and EVP of Strategy for the MDC Partners network of renowned marketing and communications agencies. He joined MDC through its acquisition of Zyman Group, a successful global strategy consulting firm where Craig was a founding partner and Chief Consulting Officer.
Craig graduated from Davidson College in North Carolina and completed postgraduate work at Harvard Business School's Program for Management Development
Lori Senecal
For more than two decades Lori Senecal has been an innovative and award-winning leader in the Strategic Marketing and Communications Industry. She has been recognized for her role in creating dynamic, talent focused cultures and inventive business models that have driven superior growth for world-class companies. In her roles as Global CEO she has counseled multinationals across a broad spectrum of industries and helped executive teams mobilize around courageous visions to reinvent entire categories and industries, to unlock business value.
She was the Global CEO of the world-renowned Marketing and Communications powerhouse Crispin Porter Bogusky. During her tenure, the agency created bold firsts and garnered world-class results for clients such as Domino's, American Airlines, Hotels.com, and Hershey's by capitalizing on expertise in technology, design and innovation. During that time, Advertising Age recognized CP+B as "Creativity Innovator of the Year".
As Global CEO of Kirshenbaum Bond Senecal, Lori grew the company from a 250-person domestic operation to one of over 900 people worldwide. The company was recognized by Advertising Age as an "A-List Standout Agency" three consecutive years, and by Crain's as a "Best Place to Work in NYC".
Lori has been named to AdWeek's Power 100 List which recognizes top leaders in media, marketing and technology. She has also been named one of Fast Company's "Most Creative People in Business". She was profiled in the New York Times "Corner Office", a feature that celebrates CEO's who are culture makers and industry drivers.
Lori has been a keynote speaker on Fast Company's "Most Creative People Tour" in LA, as well as at the "3% Conference" in NYC. She was both a Jury Member and a Main Stage Speaker at the Cannes Festival of Creativity.
Lori began her career at McLaren McCann in Toronto and was soon tapped by McCann Worldwide to join the leadership team in NY, where she rose to the office of President. As a graduate of McGill University with a Bachelor of Commerce, she is fluent in English and French.
Lori has been on the Board of Hill Street since 2018 and brings a wealth of global strategy and marketing experience from her leadership roles on world class beverage brands such as Molson Canadian, Molson Export, Rolling Rock, Bass Ale, Dos Equis, Absolut, and Coca-Cola.
There aren't any drugs that have been proven effective for Alzheimer's or Parkinson's. Meanwhile, there are numerous effective antihypertensive drugs and the antihypertensive drugs market is expected to reach $28 billion by 2026. Blood pressure meds have side effects by the way.
He's probably talking about heart disease caused by high blood pressure
https://www.drugs.com/price-guide/epidiolex
Epidiolex Prices, Coupons and Patient Assistance Programs
Epidiolex (cannabidiol) is a member of the miscellaneous anticonvulsants drug class and is commonly used for Dravet Syndrome, Lennox-Gastaut Syndrome and Tuberous Sclerosis Complex.
Epidiolex Prices
The cost for Epidiolex oral liquid (100 mg/mL) is around $1,492 for a supply of 100 milliliters, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
You can't compare the price of FDA approved pharmaceutical-grade CBD products with some food grade CBD consumer products like TurboCBD. Have you heard of GWPH and their wonder drug Epidiolex? It's just purified CBD with its own proprietary delivery system.
The blood pressure market is simply massive and near at hand, Alzheimers and Parkinsons are further down the road.
No, it's not pre-split.
LXX Shares issued 3,001,476 (not fully diluted). And Lexx has 5,104,000 issued?
Gotta agree someone must be close to the magical 10%. More shares traded yesterday than the total issued!
$8.14 in after-hours trading. Wow!
Fair seas and a following wind!
Best Wishes
It's the 'Falling Knife Rally'LOL
The share price is on a roll! Chris will be able to raise his salary soon. LOL
And all the shares from the financing were to be offered in the US only. Thus New York is now the volume leader by a long shot.